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ThePhe43 cavity is amysterious feature in crystallographic structures of HIV-1 gp120-CD4 complexes. In this
issue of Structure, Acharya and colleagues provide structural explanations for the potent neutralization by
CD4 mimetic miniproteins with chemical extensions that fit into this cavity.The first X-ray crystallographic structures
of HIV-1 gp120, initially solved for the
HXBc2 laboratory-adapted strain (Kwong
et al., 1998) and subsequently refined
and extended to the YU2 primary isolate
(Kwong et al., 2000) (Huang et al., 2004),
revealed not only tantalizing insights into
receptor interactions, but also a very puz-
zling structural feature. In the ternary
complex of gp120 ‘‘core’’ bound to a
fragment of CD4 and a Fab against a
conserved determinant involved in
coreceptor binding, an interfacial pocket
of 150 A˚3 was evident at the nexus
of three gp120 domains: the inner
domain, the outer domain, and the
bridging sheet. The pocket was cappedFigure 1. The Phe43 Cavity
CD4 (pink; only domain 1 is shown) binding induces formation of an 150 A˚3
interfacial pocket at the nexus of the gp120 inner domain (pale blue), outer
domain (marine blue), and bridging sheet (purple); the phenyl ring of the
Phe43 side chain (red) forms a lid to the cavity and is the only contributing
component from CD4. This image was generated using MacPyMOL from
Protein Data Bank number 1RZK (Huang et al., 2004).by Phe43 of CD4, a residue
previously shown to be
critical for the gp120-CD4
binding interaction. The
structural and functional sig-
nificance of this so-called
Phe43 cavity (Figure 1) was
unclear, but its conservation
and unlikely existence in the
absence of CD4 suggested
that it reflects large recep-
tor-induced conformational
changes in gp120. Beyond
its relationship to gp120
function, the Phe43 cavity
was recognized as a poten-
tially useful target for
antiviral strategies. Thus,
substituting a bulky hydro-
phobic tryptophan residue
(gp120 S375W) into the cav-
ity partially stabilizes gp120
toward the CD4-bound state
(Xiang et al., 2002), a feature
that was explored for poten-
tial vaccine immunogen ap-
plications (Dey et al., 2007).HIV entry inhibitors that act by filling the
Phe43 cavity were designed either as
small organic molecules (Madani et al.,
2008; Curreli et al., 2012) or as engineered
CD4 mimetic ‘‘miniproteins’’, pioneered
by Vita et al. (1998) and based on small
protein scaffolds. The latter were taken
through a series of structure-guided opti-
mizations, involving the inclusion of Phe at
position 23 of the miniproteins to mimic
CD4 Phe43 in plugging the cavity (Martin
et al., 2003), and culminated in the addi-
tion of flexible hydrophobic extensions
to this miniprotein residue, which are
capable of fitting into the cavity (Van Her-
rewege et al., 2008). The result was a dra-
matic increase in neutralization potency ofStructure 21, June 4, 2013HIV-1 pseudovirus infection, as much as
>1,000-fold for miniprotein M48U1
against some isolates.
In this issue of Structure, Acharya et al.
(2013) analyze the structural basis for
the extreme neutralization potency of
M48U1 as well as the related M48U7,
which contains a different flexible hydro-
phobic extension at the same position.
Surface plasmon resonance analyses
indicated that M48U1, the more potent
CD4 mimetic, bound to gp120 with
extremely high affinity (KD = 0.15 nM),
which reflected both a high association
rate and an extremely slow dissociation
rate. Crystallographic analyses of these
mimetics bound to a gp120 core proteinª2013 Else(YU2 isolate) yielded inter-
esting insights into their
modes of action. Analyses
of the flexibilities of the
extended moieties in the
bound structures, coupled
with the determination of
combined fit parameters
(shape complementarity and
extent of surface burial), high-
lighted the superiority of
M48U1 overM48U7 and other
related miniproteins. The ef-
fects of the miniproteins on
the local conformation of
gp120 were analyzed by com-
parison of the miniprotein
bound with the unliganded
structures. The analyses re-
vealed that, when bound
to the extension-containing
mimetics, the Phe43 cavity
resembled more closely that
region in the unliganded
(ground state) state com-
pared to the CD4-bound
state; earlier mimetics lackingvier Ltd All rights reserved 871
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Previewsthe extensions showed the opposite
resemblance. The authors concluded
that recognition of the ground state by
M48U1 and M48U7 is more favorable
energetically, contributing to their higher
affinities. More expansive neutralization
studies (180 isolate panel) revealed potent
activity against all except those from
Clade A/E. The presence of His at position
375 of gp120 of these isolates (instead of
the canonical Ser) is interpreted to explain
this resistance, because the His partially
fills the Phe43 pocket, thereby hindering
access of the extensions (but not CD4 or
the mimetics lacking the extensions).
This is consistent with previous findings
that resistance to M48U1 involves the
substitution of Ser375 with more bulky
residues. The results are discussed in
terms of a new mechanism of action of
CD4 binding site ligands beyond the pre-
viously described avidity (multivalent
forms) and avoidance of conformational
change (e.g., mAb VRC01), namely opti-
mization of the fitting of the hydrophobic
extensions within the interfacial Phe43
cavity.
These new agents and the structural
elucidation of the mechanisms underlying
their enhanced anti-HIV potencies prom-
ise to guide further design of novel
neutralizing agents based on optimal872 Structure 21, June 4, 2013 ª2013 Elseviefitting of extensions into the Phe43 cavity.
The recent ex vivo and nonhuman primate
studies with M48U1 as a vaginal microbi-
cide to prevent HIV-1 sexual transmission
(Dereuddre-Bosquet et al., 2012) are
highly promising for the potential antiviral
use of these miniproteins. Structure-
guided design and analysis thus continue
to pave the way for the development of
new CD4 mimetics that not only cap the
Phe43 cavity, but also fit energetically
favorable extensions deep within its
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E3 ubiquitin ligases are the last of an enzyme trio that covalently modifies proteins with ubiquitin, facilitating
various cellular functions. In this issue of Structure, Duda and colleagues provide the structural basis for the
autoinhibited Ariadne-family of E3-ubiquitin ligases.Ubiquitination, a covalent attachment of
the 76-amino-acid polypeptide ubiquitin
(Ub) to lysine residues of target proteins,
is an important post-translational modi-
fication that controls a wide range of
cellular processes. Three enzymatic sys-
tems facilitate covalent modification ofproteins by Ub: E1 activating enzymes,
E2 conjugating enzymes, and E3 Ub
ligases. First, Ub is activated via adeny-
lation by E1 and is linked subsequently
to a cysteine residue on the enzyme as a
thioester complex. Ub is then transferred
to the catalytic cysteine on an E2 viatransthiolation. The final step of the ubiq-
uitination cascade involves the transfer
of Ub from the thioester-linked E2 enzyme
(E2Ub) to a Lys residue of the substrate
mediated by an E3 ligase. Two distinct
mechanisms exist for ligation of Ub to
substrates. A homologous to the E6AP
